Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28721530 | 0.94 | ABCB1 (0.45) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL28721531 | 0.94 | ABCB1 (0.45) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL7410587 | 0.91 | L3MBTL1 (0.43) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL8111386 | 0.90 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL1085849 | 0.86 | ABCB1 (0.51) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL29401370 | 0.86 | ABCB1 (0.51) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL1928167 | 0.86 | ABCB1 (0.51) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL7275440 | 0.86 | SLC15A1 (0.47) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL31520504 | 0.85 | KMT2A (0.44) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 | |
| SCHEMBL7420644 | 0.85 | ANPEP (0.43) | ALDH1A1L3MBTL1LMNAPOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049836-A1 | PRODRUGS OF DEOXYNUCLEOSIDES FOR TREATMENT OF MITOCHONDRIAL DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS | UCB BIOSCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20230000890-A1 | Prodrugs of Deoxynucleosides for Treatment of Mitochondrial Diseases Caused by Unbalanced Nucleotide Pools | UCB BIOSCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-2001488-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | Alt Solutions, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007106561-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | ALT SOLUTIONS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049836-A1 | PRODRUGS OF DEOXYNUCLEOSIDES FOR TREATMENT OF MITOCHONDRIAL DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS | TK2, NME4, PNP | ALDH1A1 2712/4885L3MBTL1 912/4885LMNA 1216/4885 |
| US-20230000890-A1 | Prodrugs of Deoxynucleosides for Treatment of Mitochondrial Diseases Caused by Unbalanced Nucleotide Pools | TK2, NME4, PNP | ALDH1A1 2712/4885L3MBTL1 912/4885LMNA 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.